Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

SigmaRoc overcomes mixed conditions as H1 profits surge

(Sharecast News) - European lime and minerals group SigmaRoc on Monday reported a big jump in first-half profits despite a challenging market backdrop, but said it doesn't expect an improvement in conditions before the end of the year. Underlying revenues were up 13.4% year-on-year at £510.3m in the six months to 30 June, helped by a strong performance in the UK and Ireland where the business outperformed versus the general market.

However, on a proforma basis, which includes non-continuing operations from last year, revenues were actually down 1.1% at £510.3m.

Core volumes were down 3% due to softness in the construction and steel markets along with some temporary external headwinds such as customer maintenance shutdowns.

Underlying EBITDA improved 21.2% to £117.8m, helped by a 150-basis point increase in the EBITDA margin to 23.1%. Underlying pre-tax profit jumped 41.6% to £67.4m.

Looking ahead, the second half is expected to be similar in terms of underlying market conditions, which were mixed in the Nordics and Poland, while Belgian and German markets saw historically low levels of demand.

"Following a robust first half, achieved despite challenging market conditions, we enter the second half with cautious optimism," said chief executive Max Vermoken.

"With 2.7 billion tonnes of high-quality resource, essential to Europe's construction, industrial and environmental markets, SigmaRoc is well positioned to capitalise on increasing volumes when they occur."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.